Patents by Inventor Robert F. Kelley

Robert F. Kelley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides that bind APRIL
    Patent number: 8105603
    Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Darshana Ramesh Patel
  • Humanized anti-factor D antibodies
    Patent number: 8067002
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 29, 2011
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE
    Publication number: 20110256133
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: April 14, 2011
    Publication date: October 20, 2011
    Applicant: GENENTECH, INC.
    Inventors: VISHVA DIXIT, ROBERT F. KELLEY, MARISSA L. MATSUMOTO
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20110206702
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20110165622
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 7, 2011
    Inventors: LING-LING AN, SEK CHUNG FUNG, ROBERT F. KELLEY, HENRY B. LOWMAN, SANJAYA SINGH, HERREN WU
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20110123528
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 26, 2011
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Methods for making Apo-2 ligand using divalent metal ions
    Patent number: 7855066
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20100267050
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: April 23, 2010
    Publication date: October 21, 2010
    Applicant: Genentech, Inc.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • Methods and compositions for targeting polyubiquitin
    Patent number: 7763245
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: July 27, 2010
    Assignee: Genentech, Inc.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • ALTERED BR-3 BINDING POLYPEPTIDES
    Publication number: 20100166741
    Abstract: The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: July 12, 2007
    Publication date: July 1, 2010
    Applicants: Genentech , Inc., Biogen Idec Ma Inc.
    Inventors: Robert F. Kelley, Amy Yijuan Shen, Dorothea Reilly, Mark S. Dennis, Germaine Fuh, Chingwei V. Lee, Christine M. Ambrose, Jeffrey S. Thompson
  • BCMA POLYPEPTIDES AND USES THEREOF
    Publication number: 20090297504
    Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.
    Type: Application
    Filed: March 16, 2009
    Publication date: December 3, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Darshana Ramesh Patel
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20090191209
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • Apo-2 ligand variants and uses thereof
    Publication number: 20090137476
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 28, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • Polypeptides That Bind Baff And/Or April
    Publication number: 20080181886
    Abstract: The present invention relates to novel polypeptides and TACI variants that bind APRIL, novel polypeptides and TACI variants that bind BAFF, nucleic acid molecules encoding the polypeptides, host cells comprising the nucleic acid molecules, compositions comprising the polypeptides or nucleic acid molecules, and methods of using the polypeptides and nucleic acid molecules.
    Type: Application
    Filed: October 28, 2005
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventor: Robert F. Kelley
  • Humanized Anti-Factor D Antibodies and Uses Thereof
    Publication number: 20080118506
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Applicant: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Apo-2 ligand variants and uses thereof
    Publication number: 20040186051
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: April 1, 2004
    Publication date: September 23, 2004
    Inventors: Robert F Kelley, Stephanie Ho Lindstrom
  • Substitutional variants of APO-2 ligand
    Patent number: 6740739
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: May 25, 2004
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Robert F. Kelley, Mark P. O'Connell, Robert M. Pitti, Ralph A. Schwall
  • Tissue factor protein variants
    Publication number: 20040006217
    Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: April 30, 2003
    Publication date: January 8, 2004
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Geoffrey F. Lee
  • Tissue factor protein variants
    Patent number: 6596847
    Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: July 22, 2003
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Geoffrey F. Lee
  • TISSUE FACTOR PROTEIN VARIANTS
    Publication number: 20020142373
    Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: July 14, 1999
    Publication date: October 3, 2002
    Applicant: GENENTECH, INC.
    Inventors: ROBERT F. KELLEY, GEOFFREY F. LEE